Treatment-related Acute Myeloid Leukemia with Type D CBFB-MYH 11 after Chemotherapy and Radiotherapy in Non-Hodgkin Lymphoma : a Rare Case Report

Jingfang Sun,Linlin Qu,Zhengwu Guo,Gaofeng Hu,Wei Xu
2016-01-01
Abstract:Treatment-related Acute Myeloid Leukemia (t-AML) is among complications which occur after treatment of primary malignancies due to exposure to chemotherapeutic drugs and/or radiation. These malignancies include solid tumors and hematological neoplasms. T-AML accounts for approximately 10%-20% of total AML. Patients with t-AML are of special concern, because generally they have poor response to treatment and thus median survival is short. CBFB-MYH11 is a fusion gene which generally occurs in AML, but only a few t-AML cases have been reported with CBFB-MYH11, and none of them aroused after non-Hodgkin lymphoma (NHL) treatment. Here, we report a rare case with t-AML with CBFB-MYH11 (type D subtype) occurred four years after 9-month chemotherapy and radiotherapy for NHL. Lab findings are mainly discussed especially molecular genetic abnormality, which is considered as a reference for individualized treatment and prognosis. Through this report, we hope to remind the clinics and lab staff, that in order to be aware of t-AML, during treatment of NHL, dose of chemotherapy and radiotherapy should be weighed and follow up is necessary.
What problem does this paper attempt to address?